Novel NADPH Oxidase-2 Inhibitors as Potential Anti-Inflammatory and Neuroprotective Agents

Area of Science:

• Biochemistry
• Pharmacology
• Neuroscience

Background:

• NADPH oxidase (Nox) enzymes, particularly Nox2, are implicated in various diseases, including neurodegenerative conditions.
• Developing brain-permeable inhibitors is crucial for targeting central nervous system disorders.

Purpose of the Study:

• To identify and characterize novel brain-permeable Nox2 inhibitors for potential neuroprotection.
• To evaluate the efficacy and safety of TG15-132 as a Nox2 inhibitor.

Main Methods:

• Cell-based assays using differentiated HL60 and THP-1 cells to assess inhibitor activity.
• Measurement of oxygen consumption and reactive oxygen species (ROS) production.
• Gene expression analysis for Nox2 subunits, inflammatory cytokines, and iNOS.
• Pharmacokinetic studies (plasma half-life, brain permeability) in rodent models.
• Toxicology assessment in mice upon chronic dosing.

Main Results:

• TG15-132 effectively inhibited PMA-stimulated oxygen consumption and ROS formation in HL60 cells.
• Long-term TG15-132 treatment reduced gene induction of Nox2 subunits, inflammatory cytokines, and iNOS in THP-1 cells.
• TG15-132 demonstrated a favorable plasma half-life (5.6 h) and significant brain permeability (>5-fold brain-to-plasma ratio).
• No toxic effects were observed in mice after seven days of chronic dosing.

Conclusions:

• TG15-132 is a potent, brain-permeable Nox2 inhibitor with potential neuroprotective properties.
• Its ability to reduce oxidative stress and inflammation, coupled with a good safety profile, supports its further development.
• Further structural modifications may enhance TG15-132's potency for therapeutic applications.